Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Authors
Keywords
-
Journal
Emerging Microbes & Infections
Volume 11, Issue 1, Pages 2315-2325
Publisher
Informa UK Limited
Online
2022-08-26
DOI
10.1080/22221751.2022.2117094
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
- (2022) Huiping Shuai et al. NATURE
- SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
- (2022) Peter J. Halfmann et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- (2022) Laura A. VanBlargan et al. NATURE MEDICINE
- Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
- (2022) Ye-Fan Hu et al. Viruses-Basel
- Covid-19: What do we know about omicron sublineages?
- (2022) Elisabeth Mahase BMJ-British Medical Journal
- Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports
- (2022) Elisabeth Mahase BMJ-British Medical Journal
- Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
- (2022) Masaud Shah et al. Frontiers in Immunology
- Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019
- (2022) Anca Streinu-Cercel et al. Open Forum Infectious Diseases
- Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
- (2022) Christoph Jung et al. JOURNAL OF VIROLOGY
- Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
- (2022) Daniel J Sheward et al. LANCET INFECTIOUS DISEASES
- Antibody evasion properties of SARS-CoV-2 Omicron sublineages
- (2022) Sho Iketani et al. NATURE
- Are COVID surges becoming more predictable? New Omicron variants offer a hint
- (2022) Ewen Callaway NATURE
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
- (2022) Jingyou Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies
- (2022) Sabrina Lusvarghi et al. Science Translational Medicine
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
- (2021) Laurel Goldin et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?
- (2021) Simone Mornese Pinna et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Heavily mutated Omicron variant puts scientists on alert
- (2021) Ewen Callaway NATURE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started